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Objective: Previous studies have indicated that patients with peripheral artery disease (PAD), 
display significant differences in their kinetic and kinematic gait characteristics when compared 
to healthy, aged-matched controls. The ability of patients with chronic obstructive pulmonary 
disease (COPD) to ambulate is also limited. These limitations are likely due to pathology-driven 
muscle morphology and physiology alterations establish in PAD and COP, respectively. Gait 
changes in PAD were compared to gait changes due to COPD to further understand how altered 
limb muscle due to disease can alter walking patterns. Both groups were independently compared 
to healthy controls. It was hypothesized that both patients with PAD and COPD would demonstrate 
similar differences in gait when compared to healthy controls.  
Methods: Patients with PAD (n=25), patients with COPD (n=16), and healthy older control 
subjects (n=25) performed five walking trials at self-selected speeds. Sagittal plane joint kinematic 
and kinetic group means were compared. 
Results: Peak values for hip flexion angle, braking impulse, and propulsive impulse were 
significantly reduced in patients with symptomatic PAD compared to patients with COPD. After 
adjusting for walking velocity, significant reductions (p<0.05) in the peak values for hip flexion 
angle, dorsiflexor moment, ankle power generation, propulsion force, braking impulse, and 
propulsive impulse were found in patients with PAD compared to healthy controls. No significant 
differences were observed between patients with COPD and controls.  
Conclusions: The results of this study demonstrate that while gait patterns are impaired for patients 
with PAD, this is not apparent for patients with COPD (without PAD). PAD (without COPD) 
causes changes to the muscle function of the lower limbs that affects gait even when subjects walk 





Peripheral artery disease (PAD) and chronic obstructive pulmonary disease (COPD) are 
diseases that produce substantial exercise limitation in the affected patients [1,2]. Patients with 
either disease generally present with reduced muscular strength [3–6]. Previous studies have 
suggested that PAD significantly alters locomotor function [7–10] whereas, functional changes are 
not as pronounced in patients with COPD [11,12]. The impairments arising from these pathologies 
at a functional level, challenges the ability of affected patients to maintain independent living. 
Therefore, a primary focus for patients with PAD and patients with COPD is the assessment and 
rehabilitation of physical function. Physical activity produces a higher metabolic energy demand 
that requires an increased supply of oxygenated blood to the muscles compared to resting 
conditions. PAD substantially affects the delivery of blood to the legs even at submaximal exercise 
levels [13]. The effect of COPD differs with the delivery of oxygenated blood not limiting in 
patients at submaximal exercise levels [14]. Whether the deficiencies arising from these diseases 
impair gait biomechanics in a similar manner is not known, but it is important for exercise 
rehabilitation protocols.  
Peripheral Artery Disease  
PAD is a disease characterized by atherosclerosis, which is blockage of arteries due to 
plaque accumulation, and causes reduced supply of oxygenated blood to peripheral tissues. The 
most common symptom associated with PAD is intermittent claudication, defined as ischemia 
induced discomfort, pain, or cramping, which causes the patient to stop walking [10]. Advanced 
biomechanical analyses have determined the kinetic and kinematic alterations in patients with 
PAD [7–10]. Prior to claudication onset, patients with PAD have a significantly decreased 
propulsive (anterior-posterior) and vertical components of ground reaction forces (GRF) compared 
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to healthy controls. Patients with PAD also demonstrate functional impairments through decreased 
walking speed and cadence [10]. In addition, patients with PAD present with greater ankle 
plantarflexion angle during early stance, reduced time to peak plantarflexion, and increased time 
to peak dorsiflexion [10]. These kinematic changes result in an altered rollover shape of the foot, 
which interferes with the optimal transfer of energy that typically occurs in healthy individuals 
[15]. Patients with PAD have significantly reduced peak ankle power generation at push-off, hip 
power generation at toe off, hip power absorption in mid stance, and knee power absorption in 
early and late stance [7,8]. Changes to the optimal gait result in less efficient walking  patterns that 
corroborate with insufficient oxygen delivered to the leg muscles; increasing claudication pain and 
decreasing quality of life overall. 
Chronic Obstructive Pulmonary Disease 
In 2010, COPD was reported to be the third leading cause of death in the United States 
with over 137,000 reported cases [16]. COPD is characterized by progressive and persistent 
expiratory airflow limitations associated with chronic inflammation of the airway [17]. COPD 
limits ventilation causing dynamic hyperinflation when expiratory time is insufficient to permit 
lung emptying [18]. This can occur during physical activity and imposes constraints on tidal 
volume, and leads to dyspnea [12,19]. Patients with COPD may experience exacerbations, or acute 
instances of disease worsening [20]. One-third of patients with severe COPD experience 15 
minutes or less of physical activity each day [21]. Studies have indicated that slow-twitch oxidative 
(type-1) muscle fibers decrease in favor of fast-twitch (type-2) anaerobic muscle fibers in this 
population [22]. This shift suggests decreased endurance during physical activity in patients with 
COPD. The severity of COPD symptoms is correlated with gait abnormalities [11], with severe 
COPD linked to slower walking speeds [23,24], reduced cadence [25], reduced step length, 
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increased double support time [26] and more altered step time and width variability [27]. These 
may be associated with balance deficiencies detected for patients with COPD [28]. Muscular 
deficiencies have also been observed with a reduction in push-off force following a no-rest 
condition [5,29], and patients with COPD found to have weaker dorsiflexor and plantar flexor 
muscles and greater fatigability of distal leg muscles [4]. 
The mechanisms of impairment differ between the pathologies. In PAD, physical activity 
induced ischemia restricts blood supply. In COPD, airflow is restricted due to altered lung 
structure. Our group and others have previously demonstrated  that oxygen delivery was not the 
only factor limiting function in PAD patients, but that mitochondrial dysfunction restricts the 
efficient use of the already limited nutrients and oxygen further lowering the energy levels of 
pathologic muscle [13,30–33]. Patients with COPD also exhibit altered muscle mitochondria 
function with evidence of decreased mitochondrial density and biogenesis, impaired mitochondrial 
respiration, and increased mitochondrial production of reactive oxygen species in biopsies of the 
vastus lateralis [34,35]. 
Limitations in blood supply to the muscles can be reversed by surgery for patients with 
PAD, however these interventions do not enable patients to return to the activity levels of healthy 
subjects [36,37]. Medication can be used to improve the endurance in patients with COPD who do 
not develop muscle fatigue during exercise, but may not be effective when contractile fatigue is 
present [38]. It is important to understand how the different disease mechanisms, alter the ability 
of lower limb muscles to contribute to efficient gait. Currently, there are no guidelines on whether 
exercise intervention should be prescribed to patients with COPD and if so, what those exercise 
programs should entail. Those programs that do exist for patients with PAD [39] are not 
standardized and the effectiveness may vary. The understanding of how disease mechanisms in 
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PAD and COPD alter lower limb function is useful information in determining how to mitigate 
the effect of these diseases [40,41]. It can potentially facilitate the design of specific interventions 
or recommendations for supervised exercise programs aimed to restore gait and independence to 
patients with PAD and patients with COPD. 
The aim of this research was to differentiate the functional alterations associated with each 
disease by investigating changes in gait kinetics and kinematics associated with PAD prior to the 
onset of pain and compare them to the changes in gait of patients with COPD while at rest. We 
hypothesized that after accounting for reduced walking velocity, both PAD and COPD patient 
groups would have similarly altered kinematic and kinetic gait characteristics compared to healthy 




Three groups of subjects were recruited for the analysis: 1) patients with bilateral PAD 
(fontaine stage II), 2) patients with COPD, and 3) healthy elderly control subjects. The University’s 
Institutional Review Board and the Institutional Review Board at the Omaha VA Medical Center 
approved all study procedures. Informed consent was obtained for each individual involved in the 
study. All subjects were able to understand instructions and independently perform the required 
experimental tasks, such as walking on a treadmill. 
Twenty-five patients with PAD were recruited from the vascular surgery clinics of the 
Veterans’ Affairs Medical Center of Nebraska and Western Iowa, and the University of Nebraska 
Medical Center in Omaha. Patients were screened and evaluated by two board-certified vascular 
surgeons. The screening procedure included a detailed medical history, physical examination, 
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computerized tomographic angiography, hemodynamic assessment and direct evaluation and 
observational analysis of walking impairments. Ankle-brachial index levels below 0.9 and 
symptomatic claudication were inclusion criteria. Patients were excluded from participating in the 
study if they had gait deficiencies caused by comorbidities, such as cardiac, pulmonary, 
neuromuscular, or musculoskeletal disease. Additionally, patients with PAD who experienced pain 
or discomfort during walking for reasons other than claudication pain such as arthritis, low back 
pain, peripheral neuropathy, or musculoskeletal pain were excluded from this study.  
Sixteen patients with COPD were recruited from the Pulmonary Clinical Studies Unit at 
the University of Nebraska Medical Center and the general clinics of the Veterans’ Affairs Medical 
Center of Nebraska and Western Iowa to participate in the study. All patients with COPD were 
screened by a board-certified nurse practitioner. The patients were diagnosed with COPD by a 
combination of history, clinical exam, and lung function testing. All patients had a measured 
FEV1/FVC (represents the proportion of a person's vital capacity that they are able to expire in the 
first second of forced expiration) less than 0.7 [42]. Patients were free from other co-morbidities 
that affect gait including musculoskeletal problems, PAD (all patients had an ankle-brachial index 
greater than 0.9), or neurologic disorders.  
Twenty-five, age, height, and body mass matched, healthy individuals, were recruited for 
this study. Participants presented with no cardiac, pulmonary, neuromuscular, or musculoskeletal 
disease or pain. Individuals were excluded if they presented with a history of back or lower 
extremity injury, surgery that affected the subject’s mobility, or any other process limiting the 
ability to walk, such as neurologic disorders. These individuals had an FEV1/FVC greater than 0.7 
and an ankle-brachial index greater than 0.9. 
2.2 Study Design and Procedures: 
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All participants underwent a biomechanical data collection protocol. Subjects wore a tight 
fitting suit to enable accurate placement of 33 retro-reflective markers on specific anatomical 
locations in accordance with a modified Helen Hayes marker set as described previously [10,43]. 
Subjects walked over a 10m path at their self-selected speed while 3-dimensional marker 
trajectories (Motion Analysis Corp, Santa Rosa, CA ; 60Hz) and ground reaction forces were 
simultaneously collected (600  Hz; Kistler Group, Winterhur, Switzerland).  
Each subject walked across the pathway until five valid trials were obtained for each foot. 
Subjects were instructed to walk forward naturally so they did not intentionally target the force 
plate. A valid trial met the following criteria: 1) no unnatural gait alterations (change in step length 
or cadence) before or after foot contact with the force plate; 2) heel-strike and toe-off events within 
the boundaries of the force plate; and 3) contact with the force plate with only one foot. To ensure 
pain or fatigue was not present during any of the trials, subjects were seated for a minimum of one 
minute between trials, or for as long as was required for pain to completely subside. 
2.3 Data Analysis: 
Foot strikes from the right limb were analyzed for all healthy controls and patients with 
COPD. In PAD, the affected limb with the lowest ankle-brachial index and greatest symptoms of 
claudication was chosen for analysis as this was considered the primary mobility-limiting limb. 
Marker trajectories were filtered with a zero lag, low-pass Butterworth filter with cutoff 
frequencies chosen using the method described by Jackson [44]. Kinematic and ground reaction 
force kinetic data were combined and analyzed (Visual 3D, C-Motion Inc., Germantown, MD) 
using an inverse dynamics method to quantify the peak joint moments and powers which occurred 
during the gait cycle [45]. Forces, joint moments, and joint powers were normalized to body mass. 
The peak values for vertical, anterior-posterior, and medial-lateral forces; and peak sagittal joint 
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angles, moments, and powers served as the dependent variables for analysis of the lower extremity 
(Supplementary Material A).  
2.4 Statistical Analysis: 
A 1x3 ANOVA analyzed differences between groups (mean  SD)  for each dependent variable 
(SPSS version 22 software, IBM, Armonk, NY; Supplementary Material A). When a significant 
main effect occurred, (=0.05; Bonferroni correction applied where appropriate) a Tukey’s post-
hoc analysis was conducted. Additionally, separate ANCOVA models were used to investigate the 
association of disease condition with dependent variable after adjusting for walking velocity. The 
ANCOVA analysis was performed due to the known differences in walking velocity between 
groups [10,22,23]. 
3. Results 
Subject groups were of similar age, height and body mass, while a significant difference in 
walking velocity was found (Table 1). Post-hoc testing showed that patients with PAD walked 
slower than controls. The patients with COPD had an FEV1/FVC of 0.51 ( 0.16). All patients 
with PAD except three, were affected bilaterally and had an ankle-brachial index of 0.44 ( 0.20) 
for the most affected leg and 0.63 (( 0.26) for the lesser (bilateral patients)/non-affected 
(unilateral patients) limb. 
3.1 ANOVA results (Table 2): 
Weight acceptance 
Kinematic measurements showed a significant main effect for peak hip flexion angle. Post 
hoc testing showed that this was due to patients with PAD showing less flexion at the hip than 
both the control group and the patients with COPD. There was no difference in hip flexion between 
patients with COPD and the control group. Anterior-posterior braking force was significantly 
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lower for the PAD group when compared to the control group, while braking impulse was 
significantly lower compared to both the control group and the COPD group. Vertical forces during 
the initial loading phase was decreased for patients with PAD compared to controls. Joint moments 
revealed a significant main effect for ankle dorsiflexors and hip extensors. Post hoc testing resulted 
in the patients with PAD having significantly lower ankle and hip moments than the control and 
COPD groups. Regarding powers, there were significant main effects for knee power absorbed 
and hip power generated during weight acceptance. Post-hoc tests found that knee power absorbed 
by patients with PAD was significantly lower than controls.   
Single-limb support 
The only significant main effects during single limb support were found for knee extensor 
moments, and knee power generation. Post-hoc tests indicate patients with PAD had significantly 
reduced knee extensor moment and knee power generation compared to controls.  
Propulsion 
There were significant main effects for push-off vertical force, anterior-posterior 
propulsive force, propulsive impulse, ankle power generation, and knee power absorption during 
the propulsion phase of gait. Post-hoc tests of all these parameters showed values were 
significantly smaller for patients with PAD than controls. Patients with PAD also generated 
significantly less ankle power than patients with COPD. 
3.2 ANCOVA results (Table 2; Figures 1-3): 
After adjusting for velocity as a covariate significant differences between groups remained 
for six of the 14 dependent variables that were significant in the ANOVA. Below are the results 




Peak hip flexion angle was significantly reduced when compared to the control group and 
the patients with COPD. Differences observed for unadjusted braking impulses, remained after 
adjusting for velocity. Patients with PAD exhibited reduced braking impulse when compared to 
both control subjects, and patients with COPD. Peak ankle dorsiflexor moment was lower for the 
patients with PAD when compared to the control group but not when compared to the patients 
with COPD. 
Single-limb support 
There were no significant main effects during the single-limb support phase of stance. 
Propulsion 
Ankle power generation at push-off was reduced for patients with PAD when compared to 
healthy age matched control subjects. Differences at propulsion were observed in propulsive 
(anterior-posterior) ground reaction force. Patients with PAD produced significantly lower 
propulsion forces than the control group. Similarly, differences observed for unadjusted propulsion 
impulses, remained after adjusting for velocity. Patients with PAD produced lower propulsive 
impulse than control subjects, and patients with COPD. 
 
4. Discussion 
This study is the first to compare biomechanical gait abnormalities between patients with 
PAD, patients with COPD, and controls. All three groups walked at their preferred speed from a 
rested state. We hypothesized that PAD and COPD patient groups would have altered kinematic 
and kinetic gait parameters compared to healthy individuals. Our results only partly support this 
hypothesis. Patients with PAD displayed significant differences in lower limb kinematics and 
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kinetics when compared to both COPD patients and healthy controls, however no significant 
differences were observed between the patients with COPD and healthy controls.  
Patients with symptomatic PAD present with a clinically documentable chronic gait 
impairment in contrast to healthy elderly controls and patients with COPD. It is apparent from the 
results that the different mechanisms of PAD and COPD do not cause the same gait alterations for 
patients that are in a rested condition. The observed differences in the gait of patients with PAD 
were similar to those observed in previous studies [7–10,46]. Patients with PAD walked more 
slowly than patients with COPD and control subjects. When patients with PAD were velocity 
matched to control subjects in an earlier study [8] deficiencies in joint powers continued to be 
observed. A previous study [29] which did not adjust for walking velocity, showed minimal 
differences for patients with COPD when walking in a rested condition compared to a control 
group. Patients with COPD in the current study, walked at a similar speed to the control group, 
while other studies have reported that patients with COPD walk more slowly than controls [5]. 
These results suggest that the capacity of rested lower extremity muscles to produce force quickly 
is more compromised for patients with PAD than those suffering from COPD. Reduced walking 
speed alone with have an adverse effect on the quality of life of patients with PAD, compared to 
patients with COPD. 
Chronic lower extremity ischemia in PAD has been associated with a well-described 
myopathy characterized at the histological level by myofiber degeneration, fibrosis and fatty 
infiltration and at the biochemical level by defective mitochrondrial function, and increased 
oxidative stress [30,31]. The myopathy of PAD is likely a key contributor to the observed 
weakness of the dorsiflexor, and hip extensor muscle groups [47,48]. Perhaps more important for 
forward progression is the inability of the ankle and knee to generate force at the rate of healthy 
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individuals, as reflected in reduced power generation during mid and late stance[49]. The ankle in 
particular provides a significant proportion of the lower extremity power at push-off [50]. 
Development of improved exercise and rehabilitation protocols should address the reduced power 
generation capabilities at the ankle, perhaps by incorporating functional strength exercises. 
No differences were observed in the current study for patients with COPD in a rested 
condition. This study and others in the past demonstrate that PAD myopathy restricts gait capacity 
even when the patient starts walking after being well rested [7,51]. The differences between groups 
can likely be attributed to muscle morphological, biochemical and strength alterations found in 
PAD but not COPD. A number of the evaluated patients with COPD were managing their disease 
using appropriate medications that optimized their lung function. Nonetheless COPD is associated 
with fatigue at exercise intensities that would otherwise not create fatigue in this age cohort [52], 
and previous investigations have suggested that patients with COPD have significantly altered gait 
following a no rest (after onset of fatigue) condition [29]. Future investigations exploring gait 
alterations as a function of exercise time and perceived fatigue in patients with COPD as well as 
cumulative gait alterations that result if both diseases are present concurrently will likely shed 
additional light into the mobility limitations caused by these diseases. The sample size of 16 
patients with COPD may be adequate to reflect the gait of a homogeneous group, however due to 
the range of COPD phenotypes which may have been present and low severity of disease, gait 
impairments could have been minimized in the COPD cohort. Blood oxygen levels were not 
recorded so the level of oxygenation during the test is not known for the patients with COPD.  
 The results show that gait deficits are apparent in patients with PAD prior to the onset of 
pain whereas deficits are not apparent in patients with COPD prior to the onset of fatigue. Our data 
suggest that reduced ankle plantar flexor function is the main source of reduced walking ability 
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for patients with PAD. Reduced peak hip flexion angles likely result from shorter step lengths, 
which have consistently been documented in patients with PAD [8,53,54]. Future studies should 
investigate step length in combination with walking speed to determine potential reasons for 
reduced hip flexion angles in patients with PAD. These data support findings of prior works from 
our group and others showing that claudicating patients typically gather around the extreme low 
end of the physical activity continuum and experience a severe decline in all domains of physical 
function.  Future studies are required to determine the ability of different exercise protocols to treat 
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